Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock

30.97  +0.58 (+1.91%)

After market: 30.89 -0.08 (-0.26%)

Fundamental Rating

4

Taking everything into account, RXST scores 4 out of 10 in our fundamental rating. RXST was compared to 191 industry peers in the Health Care Equipment & Supplies industry. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RXST is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RXST has reported negative net income.
RXST had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: RXST reported negative net income in multiple years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

RXST has a better Return On Assets (-9.89%) than 60.53% of its industry peers.
RXST has a better Return On Equity (-11.07%) than 64.74% of its industry peers.
Industry RankSector Rank
ROA -9.89%
ROE -11.07%
ROIC N/A
ROA(3y)-32.11%
ROA(5y)-13.87%
ROE(3y)-46.6%
ROE(5y)-4.03%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

Looking at the Gross Margin, with a value of 68.44%, RXST is in the better half of the industry, outperforming 78.42% of the companies in the same industry.
In the last couple of years the Gross Margin of RXST has grown nicely.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y73.04%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXST has more shares outstanding
RXST has a better debt/assets ratio than last year.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 20.37 indicates that RXST is not in any danger for bankruptcy at the moment.
RXST has a Altman-Z score of 20.37. This is amongst the best in the industry. RXST outperforms 94.74% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, RXST is doing good in the industry, outperforming 68.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.37
ROIC/WACCN/A
WACC9.32%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.67 indicates that RXST has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.67, RXST belongs to the best of the industry, outperforming 96.84% of the companies in the same industry.
RXST has a Quick Ratio of 11.71. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a better Quick ratio (11.71) than 96.32% of its industry peers.
Industry RankSector Rank
Current Ratio 12.67
Quick Ratio 11.71
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.60% over the past year.
The Revenue has grown by 67.51% in the past year. This is a very strong growth!
Measured over the past years, RXST shows a very strong growth in Revenue. The Revenue has been growing by 82.40% on average per year.
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5YN/A
Sales Q2Q%59.08%

3.2 Future

RXST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.68% yearly.
The Revenue is expected to grow by 27.81% on average over the next years. This is a very strong growth
EPS Next Y46.68%
EPS Next 2Y31.21%
EPS Next 3Y25.61%
EPS Next 5Y30.68%
Revenue Next Year58.78%
Revenue Next 2Y45.79%
Revenue Next 3Y38.63%
Revenue Next 5Y27.81%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as RXST's earnings are expected to grow with 25.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.21%
EPS Next 3Y25.61%

More info and screens

0

5. Dividend

5.1 Amount

RXST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (1/21/2025, 8:25:06 PM)

After market: 30.89 -0.08 (-0.26%)

30.97

+0.58 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners89.07%
Inst Owner Change-0.06%
Ins Owners5.15%
Ins Owner Change0.1%
Market Cap1.25B
Analysts83.75
Price Target59.16 (91.02%)
Short Float %6.72%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.03%
Min EPS beat(2)29.76%
Max EPS beat(2)36.3%
EPS beat(4)4
Avg EPS beat(4)25.9%
Min EPS beat(4)7.94%
Max EPS beat(4)36.3%
EPS beat(8)8
Avg EPS beat(8)25.13%
EPS beat(12)12
Avg EPS beat(12)20.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.34%
Min Revenue beat(2)-1.26%
Max Revenue beat(2)5.95%
Revenue beat(4)3
Avg Revenue beat(4)2.57%
Min Revenue beat(4)-1.26%
Max Revenue beat(4)5.95%
Revenue beat(8)7
Avg Revenue beat(8)3.77%
Revenue beat(12)11
Avg Revenue beat(12)6.25%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-10.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-51.94%
EPS NY rev (1m)0%
EPS NY rev (3m)11.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.73
P/FCF N/A
P/OCF N/A
P/B 4.5
P/tB 4.5
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS3.18
BVpS6.88
TBVpS6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.89%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.44%
FCFM N/A
ROA(3y)-32.11%
ROA(5y)-13.87%
ROE(3y)-46.6%
ROE(5y)-4.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y73.04%
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.87%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.67
Quick Ratio 11.71
Altman-Z 20.37
F-Score4
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)73.84%
Cap/Depr(5y)77.79%
Cap/Sales(3y)6.29%
Cap/Sales(5y)43.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
EPS Next Y46.68%
EPS Next 2Y31.21%
EPS Next 3Y25.61%
EPS Next 5Y30.68%
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5YN/A
Sales Q2Q%59.08%
Revenue Next Year58.78%
Revenue Next 2Y45.79%
Revenue Next 3Y38.63%
Revenue Next 5Y27.81%
EBIT growth 1Y27.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.97%
EBIT Next 3Y31.61%
EBIT Next 5YN/A
FCF growth 1Y51.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.93%
OCF growth 3YN/A
OCF growth 5YN/A